-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
State Board of Administration of Florida Retirement System Makes New $64,000 Investment in Talaris Therapeutics, Inc. (NASDAQ:TALS)
State Board of Administration of Florida Retirement System Makes New $64,000 Investment in Talaris Therapeutics, Inc. (NASDAQ:TALS)
State Board of Administration of Florida Retirement System acquired a new position in Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 14,260 shares of the company's stock, valued at approximately $64,000.
Other hedge funds also recently modified their holdings of the company. Amalgamated Bank bought a new stake in shares of Talaris Therapeutics in the 1st quarter worth approximately $31,000. Prospera Financial Services Inc bought a new stake in shares of Talaris Therapeutics in the 1st quarter worth approximately $50,000. Values First Advisors Inc. bought a new stake in shares of Talaris Therapeutics in the 2nd quarter worth approximately $53,000. JPMorgan Chase & Co. lifted its position in shares of Talaris Therapeutics by 26.3% in the 1st quarter. JPMorgan Chase & Co. now owns 14,826 shares of the company's stock worth $146,000 after acquiring an additional 3,090 shares during the period. Finally, New York State Common Retirement Fund lifted its position in shares of Talaris Therapeutics by 45.2% in the 1st quarter. New York State Common Retirement Fund now owns 14,794 shares of the company's stock worth $146,000 after acquiring an additional 4,605 shares during the period. Institutional investors own 67.99% of the company's stock.
Get Talaris Therapeutics alerts:Talaris Therapeutics Stock Performance
Shares of TALS opened at $1.39 on Wednesday. The stock has a fifty day moving average price of $2.18 and a two-hundred day moving average price of $4.29. Talaris Therapeutics, Inc. has a 52-week low of $1.16 and a 52-week high of $16.63. The company has a market cap of $57.99 million, a price-to-earnings ratio of -0.86 and a beta of 1.94.
Analyst Ratings Changes
Several equities analysts recently commented on the company. Morgan Stanley cut their target price on Talaris Therapeutics from $8.00 to $6.00 and set an "equal weight" rating for the company in a research report on Friday, September 9th. HC Wainwright assumed coverage on Talaris Therapeutics in a research report on Thursday, October 20th. They set a "buy" rating and a $18.00 target price for the company. Finally, Evercore ISI raised their target price on Talaris Therapeutics to $20.00 in a research report on Monday, August 15th.About Talaris Therapeutics
(Get Rating)
Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.
Featured Articles
- Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick's Sporting Goods
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
State Board of Administration of Florida Retirement System acquired a new position in Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 14,260 shares of the company's stock, valued at approximately $64,000.
根據佛羅裏達州退休系統管理委員會在第二季度收購了Talaris治療公司(納斯達克：TALS-GET Rating)的新職位，該公司在最近提交給美國證券交易委員會的文件中稱。該公司收購了14,260股該公司的股票，價值約64,000美元。
Other hedge funds also recently modified their holdings of the company. Amalgamated Bank bought a new stake in shares of Talaris Therapeutics in the 1st quarter worth approximately $31,000. Prospera Financial Services Inc bought a new stake in shares of Talaris Therapeutics in the 1st quarter worth approximately $50,000. Values First Advisors Inc. bought a new stake in shares of Talaris Therapeutics in the 2nd quarter worth approximately $53,000. JPMorgan Chase & Co. lifted its position in shares of Talaris Therapeutics by 26.3% in the 1st quarter. JPMorgan Chase & Co. now owns 14,826 shares of the company's stock worth $146,000 after acquiring an additional 3,090 shares during the period. Finally, New York State Common Retirement Fund lifted its position in shares of Talaris Therapeutics by 45.2% in the 1st quarter. New York State Common Retirement Fund now owns 14,794 shares of the company's stock worth $146,000 after acquiring an additional 4,605 shares during the period. Institutional investors own 67.99% of the company's stock.
其他對衝基金最近也調整了對該公司的持股。合併銀行在第一季度購買了Talaris治療公司價值約31,000美元的新股。普羅斯佩拉金融服務公司在第一季度購買了Talaris治療公司價值約5萬美元的新股份。Values First Advisors Inc.在第二季度購買了Talaris治療公司價值約53,000美元的新股。摩根大通在第一季度將其在Talaris Treateutics股票的持倉量提高了26.3%。摩根大通在此期間增持了3,090股，目前持有14,826股該公司股票，價值14.6萬美元。最後，紐約州共同退休基金在第一季度將其在Talaris Treeutics的股票頭寸提高了45.2%。紐約州共同退休基金現在擁有14,794股該公司的股票，價值146,000美元，在此期間又購買了4,605股。機構投資者持有該公司67.99%的股份。
Talaris Therapeutics Stock Performance
Talaris Treateutics股票表現
Shares of TALS opened at $1.39 on Wednesday. The stock has a fifty day moving average price of $2.18 and a two-hundred day moving average price of $4.29. Talaris Therapeutics, Inc. has a 52-week low of $1.16 and a 52-week high of $16.63. The company has a market cap of $57.99 million, a price-to-earnings ratio of -0.86 and a beta of 1.94.
週三，Tals的股價開盤報1.39美元。該股的50日移動均線價格為2.18美元，200日移動均線價格為4.29美元。Talaris Treateutics，Inc.的52周低點為1.16美元，52周高點為16.63美元。該公司市值為5799萬美元，市盈率為-0.86倍，貝塔係數為1.94。
Analyst Ratings Changes
分析師評級發生變化
About Talaris Therapeutics
關於Talaris Treateutics
(Get Rating)
(獲取評級)
Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.
Talaris治療公司在美國作為一家臨牀晚期細胞治療公司運營。該公司致力於開發異基因造血幹細胞移植的方法，以改變實體器官移植和嚴重的自身免疫性疾病以及嚴重的非惡性血液、免疫和代謝疾病的護理標準。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick's Sporting Goods
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- 免費獲取StockNews.com關於Talaris治療(TALS)的研究報告
- 在取消了13%的股息後，Lumen Technologies可以擁有嗎？
- 思科希望重組削減成本以增加收入
- Dick‘s體育用品的賣方上限收益
- 想要獲得10%的股息收益率，看看這裏
- 炒股：3只有吸引力的股票，交易價格在10美元左右
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Talaris治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Talaris治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧